Comparison of effacement curve with dilatation curve for prediction of labor progression by Agah, Jila et al.
48
Winter  2014, Volume 5, Number 1
1. Introduction
ormalin-test is commonly used in animal 
models of chronic inflammatory pain 
(Abbott, Franklin, & Westbrook, 1995; 
Dubuisson & Dennis, 1977) and also for 
investigating the analgesic effect of sub-
stances (Kim, Hong, Zhang, Ko, & Lee, 2012; Han 
et al., 2012). Formalin test has some advantages over 
acute nociceptive tests: it employs a painful stimulus 
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Introduction: Formalin injection induces nociceptive bahaviour in phase I and II, with 
a quiescent phase between them. While active inhibitory mechanisms are proposed to be 
responsible for initiation of interphase, the exact mechanisms which lead to termination of 
nociceptive response in phase II are not clear yet. Phase II is a consequence of peripheral and 
central sensitization processes, which can lead to termination of the noxious stimuli responses; 
45-60 minutes after formalin injection via possible recruitment of active inhibitory mechanisms 
which we have investigated in this study. 
Methods: To test our hypothesis, in the first set of experiments, we evaluated nociceptive 
response after two consecutive injection of formalin (50µL, 2%), with intervals of 5 or 
60 minutes. In the next set, formalin tests were carried out in companion with injection of 
Naloxone Hydrochloride, a non-selective antagonist of opioid receptors, pre-formalin injection 
and 30 and 45 minutes post formalin injection. 
Results: While normal nociceptive behaviour was observed in the group receiving one 
injection of formalin, a diminished response was observed in phases I and II of those receiving 
consequent injection of formalin, 60 minute after first injection. While second injection of 
formalin, 5 minute after first injection, had no effect. Administration of naloxone (1mg/kg) 
decreased nociception in phase 2A; but had no effect on delayed termination of formalin test. 
Discussion: The results of this study suggest the existence of an active inhibitory mechanism, 
other than the endogenous opioids, that is responsible for termination of nociceptive behaviour 
at the end of formalin test.
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F
and while animals show a spontaneous response, their 
nociceptive behaviour is lasted for more than 60 min-
utes, except for a period of quiescent interphase in which 
the animals show a decreased nociceptive response or 
no response at all (Abbott et al., 1995; Dubuisson et al., 
1977). This test consists of two phases which recruit dif-
ferent modulation systems, thus it has more similarities 
to clinical pain rather than transient response observed 
in acute nociceptive tests (Staniland & McMahon, 2009; 
Hunskaar, Berge, & Hole, 1986; Hunskaar & Hole, 
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1987). Sub plantar injection of different concentrations 
of formalin in the hind paw of rat or mice induces a 
series of nociceptive behaviours which lasts more than 
60 minutes (Yashpal & Coderre, 1998; Sufka, Watson, 
Nothdurft, & Mogil, 1998; Abbott et al., 1995; Dubuis-
son et al., 1977). Formalin test consists of three phases: 
animals show a short period of nociceptive behaviours in 
phase I, which is followed by a quiescent or attenuation 
of nociceptive responses in interphase, and then a long 
lasting period of nociceptive behaviour for 60 minutes or 
even more (Hunskaar et al., 1986; Hunskaar et al., 1987). 
Finalization of formalin test is defined as the termination 
of nociceptive behaviour in the animals, but the underly-
ing mechanism is still not clear. Despite the existence of 
local inflammation and edema 60 minutes after formalin 
injection, animals show a very few nociceptive behav-
iour. This point elicits an assumption for a possible ac-
tive inhibitory mechanism that suppresses nociception 
60 minutes after formalin injection. To our knowledge, 
no study has addressed the possible mechanisms which 
may be responsible for the attenuation and finalization 
of phase 2 nociceptive behaviours in formalin test. The 
existence of an active inhibitory mechanism responsible 
for interphase (Gaumond, Arsenault, & Marchand, 2002; 
Henry, Yashpal, Pitcher, & Coderre, 1999; Franklin & 
Abbott, 1993) arise the possibility of existence of anoth-
er active mechanism responsible for the termination of 
phase 2. Therefore, in this study we evaluated the effect 
of consecutive injection of formalin into the same hind 
paw 60 minutes after the first injection and then mea-
sured the nociceptive response of animals for the second 
60 minutes interval. The underlying hypothesis was that 
if the attenuation of the nociceptive behaviour at the end 
of phase 2 was due to an inactive mechanism, then an 
accumulation of nociceptive responses would occur after 
the second injection, due to pre-existing inflammation; 
but if the response was attenuated after the second injec-
tion, then an active mechanism would have been respon-
sible for the finalization of painful responses in second 
phase of formalin test. In the next step, we used naloxone 
hydrochloride as a non-selective opioid antagonist to see 
whether opioid receptors are responsible for the finaliza-
tion of nociceptive response at the end of the formalin 
test or not and to check for the possible activation of en-
dogenous opioidergic inhibitory mechanism at the end 
of nociceptive responses in formalin test. 
2. Methods
All Experiments were done in accordance with the 
National Institutes of Health Guide for the Care and 
Use of Laboratory Animals (NIH Publication No. 80-
23, revised 1996) and were approved by the Research 
and Ethics Committee of Qazvin University of Medical 
Sciences, Qazvin, Iran. All efforts were made through-
out the experiments to minimize the animal discomfort 
and to reduce the number of animals used. Adult male, 
Sprague–Dawley rats (220–300 g) purchased from Razi 
Institute (Hesarak Karj, Iran), were housed in groups 
of three in a temperature controlled room, under a 12 
h light–dark cycle with lights on at 7:00 to 19:00. Food 
and water were provided ad libitum. During the experi-
ments, attention was strictly paid to the regulations of 
local authorities for handling laboratory animals. 
Figure 1. Time scores of formalin induced nociceptive behaviours (mean ±S.E.M. of 7–8 rats per group) following saline-
formalin or formalin-formalin injection measured every 3 minutes for 150 minutes (A) and bar chart for them (B). The columns 
represent the mean of nociceptive score in each phase: phase 1 (1–7), interphase (8–14), phase 2A (15–60) and phase 2B (61–90), 
(B). Recording of the nociceptive behaviours began immediately after second injection (time 0) and was continued for the next 
90 minutes. * P<0.05; ** P<0.01 and *** P<0.001 in comparison with saline-formalin group.
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Rats were moved to the test room at least 1 hour before 
the beginning of the experiment. In the present study, 
rats were first acclimatized for 30 minutes in an acrylic 
observation chamber (30cm in diameter and in height) 
and then 50μL of 2% formalin was injected subcutane-
ously into the plantar surface of the right hind paw with 
a 30 gauge needle. Each rat was then immediately re-
turned to the observation box, and behavioural recording 
was commenced. A mirror, placed at a 45° angle beneath 
the box, permitted the observation of behaviours without 
moving the box. Pain behaviours were scored as follows: 
0, the injected paw was not favoured; 1, the injected paw 
had little or no weight placed on; 2, the injected paw 
was elevated and not in contact with any surface; and 
3, the injected paw was licked or bit. Scores were con-
tinuously observed for the duration of the experiment 
(90 minutes). The nociceptive behaviour score for each 
3-minutes interval was calculated as the weighted aver-
age of the number of seconds spent in each nociceptive 
behavioural condition, from the start of the experiment 
(Azhdari-Zarmehri, Semnanian, & Fathollahi, 2008; 
Azhdari-Zarmehri et al., 2011; Erami, Azhdari-Zarmeh-
ri, Ghasemi-Dashkhasan, Esmaeili, & Semnanian, 2012; 
Heidari-Oranjaghi, Azhdari-Zarmehri, Erami, & Hagh-
parast, 2012). The scores were recorded in saline+ for-
malin group as well as in those who received formalin+ 
formalin injection. In each group, the second formalin 
injection (subcutaneously into the plantar surface of the 
right hind paw) was performed 60 minutes after the first 
one (saline in control and formalin in treated one) and 
behavioural responses of each rat during the first phase 
(1-7), inter-phase (8-14), and phase 2A (15-60) and 2B 
(61-90) were separately evaluated (Azhdari Zarmehri H. 
et al., 2011; Azhdari Zarmehri, Semnanian, & Fathol-
lahi, 2008).  
Rats were in seven groups. The 1st group was treated as 
described above with a saline-formalin injection of 2% 
formalin. The 2nd group was given a formalin-formalin 
injection of 2%. This second administration was given at 
60 min interval. The 3rd and 4th groups were pre-treated 
with naloxone (1 and 3mg/kg) 5 min before the first for-
malin injection. The 5th and 6th groups received nalox-
one (s.c.; 1; 3mg/kg) 30 min after first formalin injection. 
To make a comparison  with the 5th and 6th groups, the 
7th group was treated with naloxone (s.c.; 3mg/kg) 45 
min after first formalin injection. 
Data are presented as Mean ±SEM. Painful scores over 
the 3 min time blocks, initiating upon the first injection, 
were analysed using repeated measures ANOVA, with 
comparisons between experimental groups and the con-
trol group at each time interval using Tukey's post-hoc 
test or planned comparisons. The defined level for statis-
tical significance was P<0.05.
3. Results
Formalin at concentration of 2% produced typical bi-
phasic pain responses. The first and second phases were 
separated by a brief inter-phase while a little to no no-
ciceptive behaviour was observed in the control group. 
In saline-formalin injection group, formalin injection 
Figure 2. Time scores of formalin induced nociceptive behaviours (mean ±S.E.M. of 9 and 10 rats per group) following forma-
lin-formalin injection (animals were given a second injection of 2% formalin 5min after the first) measured every 3 minutes for 
the next 90 minutes (A) and bar chart for them (B). The columns represent the mean of nociceptive score in each phase: phase 
1 (1–7), interphase (8–14), phase 2A (15–60) and phase 2B (61–90), (B). Recording of the nociceptive behaviours began imme-
diately after formalin injection (time 0) and was continued for 90 minutes. * P<0.05 in comparison with saline-formalin group.
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induced nociceptive behaviours for less than 10 min-
utes, then attenuation or inhibition of nociceptive be-
haviours occurred which is considered as the interphase. 
Subsequently, the second phase (minutes 15–60) began 
approximately 15 min after the formalin injection. In 
formalin-formalin injection group, animals were given 
a second injection of 2% formalin 60 min after the first 
injection. A diminution of nociceptive responses hap-
pened during phases 1 and 2 for the second injection 
(for phase 1:  [T(1,13)=2.261; p=0.042], for interphase: 
[T(1,13)=1.043; p=0.316], for phase 2A: [T(1,13)=4.455; 
p=0.001], for phase 2B: [T(1,13)=3.396; p=0.005]; Fig. 
1).
 In another experiment, animals were given the second 
injection of formalin 5 minutes after the first one. An in-
crease of nociceptive responses happened during phases 
1 (for phase 1: [T(1,17)=2.268; p=0.046], for interphase: 
[T(1,17)=1.837; p=0.093], for phase 2A: [T(1,17)=1.628; 
p=0.123], for phase 2B: [T(1,17)=1.207; p=0.244]; Fig. 
2). 
Both doses of naloxone (1 and 3mg/kg) which were pre-
injected in control rats did not produce any significant 
change compared to saline (for phase 1: [F(2,19)=2.140; 
p=0.140], for interphase: [F(2,19)=1.844; p=0.185], 
for phase 2A: [F(2,19)=0.260; p=0.773], for phase 2B: 
[F(2,19)=1.038; p=0.373]; Fig. 3). 
Naloxone (1 and 3mg/kg) administered 30 minutes 
after first formalin injection did not produce any sig-
nificant changes in different phases, except for 1mg/
kg of naloxone, which produced a decrease in nocicep-
tive response in phase2A (for phase 1: [F(2,17)=0.273; 
p=0.764], for interphase: [F(2,17)=1.266; p=0.307], 
for phase 2A: [F(2,17)=4.954; p=0.020], for phase 2B: 
[F(2, 17)=0.030; p=0.971]; Fig. 4). Naloxone (3mg/kg) 
administered 45 minutes after formalin injection pro-
duced a slight but not significant increase in nocicep-
tive response in phase2A (for phase 1: [F(2,17)=0.196; 
p=0.824], for interphase: [F(2,17)=1.409; p=0.271], 
for phase 2A: [F(2,17)=0.344; p=0.714], for phase 2B: 
[F(2,17)=0.257; p=0.776]; Fig. 5).
4. Discussion 
In this study, a saline-formalin injection into the hind 
paw of the rats produced a typical biphasic response, 
while injection of saline did not produce any nociceptive 
behaviour. When a second dose of formalin was applied 
to the same hind paw, a decreased nociceptive response 
happened in phase 1 and 2 (1); and if the second injec-
tion was given 5 minutes after the first one, an increase 
in nociceptive behaviour was observed in phase 1. While 
pre-treatment with naloxone did not produce any signif-
icant changes in nociceptive behaviour during any of 
the phases, administration of this opioid non-selective 
antagonist in 1mg/kg dosage, 30 minutes after formalin 
injection, produced a significant decrease in phase 2A. 
Although a number of studies recommend that the 
decrease in nociceptive behaviours after phase 1 of the 
formalin test is due to the active endogenous pain-sup-
pressing mechanisms (Franklin et al., 1993; Gaumond 
et al., 2002; Gaumond, Arsenault, & Marchand, 2005; 
Henry et al., 1999), to our knowledge, there is no study 
Figure 3. Time scores of formalin induced nociceptive behaviours (mean ±S.E.M. of 7 to 10 rats per group) following naloxone 
injection measured every 3 minutes for 90 minutes (A) and bar chart for them (B). The columns represent the mean of nocicep-
tive score in each phase: phase 1 (1–7), interphase (8–14), phase 2A (15–60) and phase 2B (61–90), (B). Recording of the nocicep-
tive behaviours began immediately after formalin injection (time 0) and was continued for 90 minutes.
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to indicate that finalization of phase 2 in the formalin test 
happens actively or passively. For example, it is report-
ed that pentobarbital, diazepam and alcohol inhibit the 
‘inter-phase diminution' and suggest that these GABAA 
receptor agonists unmask the pain that is suppressed by 
some inhibitory mechanism (Franklin et al., 1993). In 
another study, Henry et al (1999) showed that after two 
injections of formalin (with 20 minutes interval), there 
was diminution of nociceptive scores after the second 
formalin injection, rather than an additive sum of the no-
ciceptive responses to the two injections (Henry et al., 
1999). These results propose that the attenuation in noci-
ceptive behaviours during phase 1 and 2 which normally 
happens after the second injection of the formalin is due 
to an active inhibitory process, which can even prevent 
the increase in painful responses after second adminis-
tration of formalin. It has been shown that the second 
phase of formalin test can be delayed and the nocicep-
tive response can be manipulated by the researcher in 
this phase, these can suggest the existence of an active 
mechanism responsible for this phase. In the previous 
study, we demonstrated that chronic heterogeneous se-
quential stress increased the nociceptive behaviours in 
phase 2 of the formalin test in male rats compared to the 
control ones (data was presented in neuro2012, Japan). 
Also systemic administration of NMDA receptor an-
Figure 5. Time scores of formalin induced nociceptive behaviours (mean ±S.E.M. of 7 or 8 rats per group) following naloxone 
injection in 45 minutes after formalin injection measured every 3 minutes for 90 minutes (A) and bar chart for them (B). The 
columns represent the mean of nociceptive score in each phase: phase 1 (1–7), interphase (8–14), phase 2A (15–60) and phase 
2B (61–90), (B). Recording of the nociceptive behaviours began immediately after formalin injection (time 0) and was continued 
for 90 minutes. 
Figure 4. Time scores of formalin induced nociceptive behaviours (mean ±S.E.M. of 7 or 8 rats per group) following naloxone 
injected minute 30 measured every 3 minutes for 90 minutes (A) and bar chart for them (B). The columns represent the mean 
of nociceptive score in each phase: phase 1 (1–7), interphase (8–14), phase 2A (15–60) and phase 2B (61–90), (B). Recording of 
the nociceptive behaviours began immediately after formalin injection (time 0) and was continued for the next 90 minutes.
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tagonists decreases the nociceptive responses observed 
during the late phase of the formalin test (Berrino et al., 
2003; Sabetkasaie, Khansefid, & Ladgevardi, 2007).
Considering the fact that injection of formalin 60 min-
utes after the first injection was simultaneous with the 
decrease in nociceptive responses in phase one and two 
of the second test, we can suggest that attenuation of no-
ciceptive responses in phases one and two is due to a pre-
viously activated mechanism started by the first injection 
of formalin. If we do not think of an active mechanism 
responsible for the termination of the second phase, then 
second injection of formalin would induce an increased 
response in the second experiment due to the pre-existing 
inflammation. But such an increase was not observed in 
our experiments, showing active inhibitory mechanisms 
responsible for finalization of nociceptive responses in 
formalin test.
Naloxone was ineffective in phase one and two, which 
is consistent with previous studies. Gaumond et al (2007) 
demonstrated that the inhibitory mechanism in inter-
phase involves opioidergic system, especially in female 
rats (Gaumond, Spooner, & Marchand, 2007). Kocher 
et al. (1988) also demonstrated that systemic naloxone 
is not effective in altering nociceptive responses during 
phase one and two of formalin test, which is consistent 
with our findings (Kocher, 1988).
Naloxone (1mg/kg) administered 30 minutes after for-
malin injection was effective in reducing nociceptive be-
haviour in phase 2A, which is consistent with Foo and 
Westbrook study (1993), who demonstrated the hypoal-
gesic effect of naloxone (1mg/kg) on formalin test (Foo 
& Westbrook, 1993).
In conclusion, based on previous reports that an active 
inhibitory mechanism is responsible for the attenuation 
of nociceptive responses in interphase, we here report 
that the attenuation of nociceptive response at the end 
of the formalin test may involve an active mechanism. 
Since naloxone administered 45 minutes after formalin 
injection did not change nociceptive responses, another 
inhibitory mechanism seems to be responsible for the at-
tenuation and finalization of nociceptive responses at the 
end of the formalin test. Further research would clarify 
the exact inhibitory mechanism involved. 
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